Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aimed to assess the correlation between HCG levels after ovulation triggering and ICSI outcomes, affected by HCG formulation and dose
The aims of this study are:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| uHCG group | Trigger intramuscular (IM) administration of 10000 IU of uHCG |
| |
| rHCG group | Trigger with subcutaneous (SC) administration of 6500 IU of rHCG |
| |
| Dual trigger group | Combined SC administration of 0.1 mg of GnRHa and IM administration of 2500 IU of uHCG |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| uHCG | Drug | Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Clinical pregnancy rate | Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 4-6 weeks after the ET) divided by the number of ET procedures | 6 weeks after embryo transfer |
| Measure | Description | Time Frame |
|---|---|---|
| Oocyte maturation rate | Number of mature oocytes divided by the number of retrieved oocytes | On 1 day of oocyte retrieval |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Women who will undergo controlled ovarian stimulation (COS) through fixed GnRH antagonist protocol with ovulation triggering, according to the risk of OHSS, by: 1) urinary HCG (uHCG); 2) recombinant HCG (rHCG); or 3) a combination of GnRHa and HCG (dual trigger)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Engy Abdallah, MSc | Mansoura University | Principal Investigator |
| Mohamed S Abdelhafez, MD | Mansoura University | Study Director |
| Mohamed Elzayat, MD | Royal Center | Study Chair |
| Amoura Abou-ElNaga, MD | Mansoura University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Center | Al Mansurah | Dakahlia Governorate | 35516 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007246 | Infertility |
| ID | Term |
|---|---|
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D006063 | Chorionic Gonadotropin |
| D017329 | Triptorelin Pamoate |
| ID | Term |
|---|---|
| D006062 | Gonadotropins |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
Not provided
Not provided
Not provided
Not provided
Not provided
| rHCG | Drug | Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle) |
|
|
| uHCG and GnRHa | Drug | Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon) |
|
|
| D010926 | Placental Hormones |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011257 | Pregnancy Proteins |
| D011506 | Proteins |
| D007987 | Gonadotropin-Releasing Hormone |
| D010906 | Pituitary Hormone-Releasing Hormones |
| D007028 | Hypothalamic Hormones |
| D009479 | Neuropeptides |
| D009842 | Oligopeptides |
| D009419 | Nerve Tissue Proteins |